Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Type 1 Diabetes
Phase NA
Enrollment 400
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: T1D team, structured education, peer support , and diabetes technologies — Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.
  • Behavioral: Routine Management — Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.

Primary Outcomes

  • Change in HbA1c (Baseline, 13, 26, and 52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-18
Completion: 2027-04-01
Eligibility
Age: 6 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Xiangya Hospital of Central South University
Principal Investigators:
  • Xia Li, MD, PhD (PRINCIPAL_INVESTIGATOR) - Second Xiangya Hospital of Central South University
Contact Information
Study Contact:
Xia Li
+86 13974885753
lixia2014@vip.163.com
Xiaoling Cai
dr_junel@sina.com
Department of Endocrinology and Metabolism, Peking University People's Hospital
Yi Zhang
zhangyi135@qzdyyy.com
Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical University
Interventions
  • Behavioral: T1D team, structured education, peer support , and diabetes technologies — Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.
  • Behavioral: Routine Management — Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.
Study Locations (10 sites)
Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, Beijing Municipality China
Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian China
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong China
Second Department of Endocrinology and Metabolism, Tangshan Gongren Hospital, Tangshan, Hebei China
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003 China
Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei China
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University, Changsha, Hunan 410011 China
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning China
Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University, Chengdu, Sichuan China
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang China
Eligibility Criteria
Eligibility criteria for study hospitals: 1. Members of the China Diabetes Type 1 Study (CD1S). 2. Experience in type 1 diabetes management: treat more than 50 T1D patients per year and have held camp activities at least once. 3. Have type 1 diabetes educators. Eligibility criteria of study participants: 1. Diagnosis of Type 1 Diabetes. 2. Age ≥6 years, regardless of gender. 3. Duration of disease \>3 months. 4. Planned to attend follow-up visits at this hospital within the next year. 5. Possess sufficient cognitive ability to operate all study-related devices. 6. Willing to use continuous glucose monitoring and insulin pumps, upload data, and participate in remote monitoring. 7. Willing to attend structured education sessions and camp activities on time (for the intervention group only). 8. Willing and able to adhere to the study protocol. 9. Willing to sign the informed consent form. Exclusion Criteria of study participants: 1. Patients who plan to receive diabetes treatment at other hospitals. 2. Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening. 3. Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring. 4. Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies. 5. Patients diagnosed with hematologic or bleeding disorders. 6. Patients who have received red blood cell transfusions or erythropoiesis-stimulating agents within 3 months prior to screening. 7. Patients who have used any oral, injectable, or intravenous corticosteroids within 8 weeks prior to screening, or who plan to use corticosteroids during the trial. 8. Patients with severe skin diseases that may affect the application sites of continuous glucose monitoring or insulin pump patches. 9. Patients with auditory or visual impairments. 10. Patients with alcohol or drug abuse. 11. Patients who plan to receive blood transfusions during the study period. 12. Patients who plan to undergo elective surgery requiring general anesthesia or dialysis during the study period. 13. Pregnant women, women planning to become pregnant within 1 year of the study, or women who are breastfeeding. 14. Patients who are currently participating in or have participated in other drug or device trials within the last 2 weeks. 15. Patients who, in the investigator's opinion, are not suitable for participation in this clinical trial, such as those with a history of vision impairment, eating disorders, celiac disease, etc.
Conditions Pre-diabetes, Type 2 Diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Pre-diabetes (Pre-D) is a precursor to type 2 diabetes (T2D) and characterized by increased exercise fatigability of lower limb muscles, that can impede exercise performance. The cause for the increased fatigability in people with Pre-D is not known. Given the profound vascular disease present in people who have had uncontrolled diabetes for several years, we will determine whether dynamic, fatiguing contractions of the lower limb muscles in people with Pre-D are limited by vascular dysfunction at multiple levels along the vascular tree including the artery, arteriole, and/or capillary. This clinical trial involves a novel exercise training regime involving blood flow restriction to the exercising limb will be used as a probe to further understand the vascular mechanisms for increased fatigability in people with Pre-D and T2D. The long-term goal is to better understand what limits exercise and functional performance in people with diabetes to help develop targeted, more effective exercise programs.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Control Exercise — Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
  • Other: Blood Flow Restriction Exercise — Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.

Primary Outcomes

  • Fatigability - Reduction in Power (One session before and then after 8 weeks of training)
  • Strength - 1 Repetition Maximum (One session before and then after 8 weeks of training)
  • Strength - Maximal Voluntary Contraction (MVC) (One session before and then after 8 weeks of training)
  • Leg Blood Flow (One session before and then after 8 weeks of training)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-09-01
Completion: 2027-08-31
Eligibility
Age: 30 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Collaborators: University of Illinois at Chicago, Medical College of Wisconsin, University of Wisconsin, Madison, National Institute on Aging (NIA), Marquette University
Contact Information
Study Contact:
Sandra Hunter, PhD
(734) 647-9819
sandrahu@umich.edu
Sarah Lessila, MSc
slessila@umich.edu
Sandra Hunter, PhD
(734) 647-9819
sandrahu@umich.edu
University of Michigan
Interventions
  • Other: Control Exercise — Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
  • Other: Blood Flow Restriction Exercise — Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Men and women adults 30 years to 85 years or less * Pre-diabetes \[glycosylated hemoglobin (HbA1c) of 5.7-6.4% and fasting plasma glucose 100-125 mg/dL at the time of initial screening\] * Controls \[normoglycemic with a HbA1c level ≤5.6% and fasting blood glucose ≤ 99 mg/dL (5.5 mmol/L)\] * Type 2 Diabetes Mellitus \[elevated glycosylated hemoglobin (HbA1c) \>6.5% and \<10%\] Exclusion Criteria: * Signs or symptoms of neuropathy * Medications associated with advanced stages of T2D including insulin * Poor glycemic control (HbA1c\>10%) * Peripheral edema * Severe obesity (BMI, \>45kg·m-2) * Untreated hypothyroidism * Smoking * Hypertension * Cardiovascular or musculoskeletal disease that preclude exercise testing * Hormone replacement drugs or vasoactive medications
Conditions Periodontitis, Type 2 Diabetes Mellitus ...
Phase Not Applicable
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This observational cross-sectional study will evaluate salivary apelin, chemerin, ghrelin, and lipocalin-2 levels in individuals with different periodontal and systemic conditions. Participants will be divided into four groups according to periodontal status and the presence or absence of type 2 diabetes mellitus. Clinical periodontal measurements and unstimulated saliva samples will be obtained before periodontal treatment. Salivary biomarker levels will be measured using enzyme-linked immunosorbent assay kits. The study aims to determine whether salivary apelin, chemerin, ghrelin, and lipocalin-2 levels are associated with periodontitis, type 2 diabetes mellitus, and periodontal clinical parameters.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Salivary Biomarker Analysis — Unstimulated saliva samples will be collected from participants before periodontal treatment and before periodontal probing. Salivary apelin, chemerin, ghrelin, and lipocalin-2 levels will be measured using enzyme-linked immunosorbent assay kits according to the manufacturer's instructions. This procedure is used for biomarker assessment only and does not involve any therapeutic intervention.

Primary Outcomes

  • Salivary apelin, chemerin, ghrelin, and lipocalin-2 levels (Baseline, before periodontal treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-07-01
Completion: 2026-08-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Necmettin Erbakan University
Contact Information
Study Contact:
Osman Babayiğit
+90 506 320 84 74
obabayigit@erbakan.edu.tr
Osman Babayiğit
+90 506 320 84 74
obabayigit@erbakan.edu.tr
Necmettin Erbakan University Faculty of Dentistry, Department of Periodontology
Interventions
  • Diagnostic Test: Salivary Biomarker Analysis — Unstimulated saliva samples will be collected from participants before periodontal treatment and before periodontal probing. Salivary apelin, chemerin, ghrelin, and lipocalin-2 levels will be measured using enzyme-linked immunosorbent assay kits according to the manufacturer's instructions. This procedure is used for biomarker assessment only and does not involve any therapeutic intervention.
Study Locations (1 sites)
Necmettin Erbakan University Faculty of Dentistry, Department of Periodontology, Konya, Konya 42090 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Individuals aged 18 to 80 years. Individuals who apply to the Department of Periodontology, Faculty of Dentistry, Necmettin Erbakan University. Individuals who agree to participate in the study and sign the informed consent form. Presence of at least 20 teeth. For the periodontally healthy groups: diagnosis of periodontal health based on routine clinical and radiographic examination. For the periodontitis groups: diagnosis of generalized Stage II or Stage III periodontitis based on routine clinical and radiographic examination according to the 2017 World Workshop Classification of Periodontal and Peri-Implant Diseases and Conditions. For the type 2 diabetes mellitus groups: diagnosis of type 2 diabetes mellitus. For the systemically healthy groups: absence of systemic diseases, including type 2 diabetes mellitus. Exclusion Criteria: * Periodontal treatment, including scaling and root surface debridement, within the last 6 months. Antibiotic use within the last 6 months. Pregnancy or lactation. Presence of autoimmune diseases such as rheumatoid arthritis, familial Mediterranean fever, ankylosing spondylitis, Behçet disease, or psoriasis. Presence of systemic diseases other than type 2 diabetes mellitus in the diabetes groups. Presence of systemic diseases such as nephrotic syndrome, chronic renal disease, or cardiovascular disease. Smoking 10 or more cigarettes per day.
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 2500
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized, double-blind, placebo-controlled trial involving 2,500 individuals aged 40-79 with type 2 diabetes (T2D). The trial includes a 2-year intervention period followed by a 3-year post-intervention follow-up. The primary objective is to investigate (a) the effect of daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) on glycemic control in patients with T2D and (b) whether daily supplementation with vitamin D3 (1600 IU) or yeast β-glucan (600 mg) reduces the predicted 10 year risk of atherosclerotic cardiovascular disease (ASCVD) in patients with T2D. The secondary objectives include evaluating the effects of vitamin D3 or yeast β-glucan supplementation on cardiometabolic risk factors, inflammatory markers, and liver and kidney function indicators, and assessing whether such supplementation reduces the risk of cardiovascular disease, microvascular complications and mortality over the 3-year post-intervention period.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Vitamin D3 — Vitamin D3(cholecalciferol),1600 IU per day.
  • Dietary Supplement: yeast β-glucan — yeast β-glucan, 600mg per day.
  • Dietary Supplement: Vitamin D placebo — Vitamin D placebo
  • Dietary Supplement: yeast β-glucan placebo — yeast β-glucan placebo

Primary Outcomes

  • Glycemic control (24 months)
  • Cardiovascular disease risk (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-08
Completion: 2032-12-31
Eligibility
Age: 40 Years – 79 Years
Sex: ALL
Volunteers: false
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Huazhong University of Science and Technology
Principal Investigators:
  • An Pan, PHD (PRINCIPAL_INVESTIGATOR) - School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
Contact Information
Study Contact:
Gang Liu, PHD
86-15926238366
liugang026@hust.edu.cn
Tianyu Guo
86-18210047875
D202482059@hust.edu.cn
Qiuli Chen
Guangxi Medical College
Interventions
  • Drug: Vitamin D3 — Vitamin D3(cholecalciferol),1600 IU per day.
  • Dietary Supplement: yeast β-glucan — yeast β-glucan, 600mg per day.
  • Dietary Supplement: Vitamin D placebo — Vitamin D placebo
  • Dietary Supplement: yeast β-glucan placebo — yeast β-glucan placebo
Study Locations (5 sites)
Guangxi Medical College, Nanning, Guangxi China
Kailuan General Hospital, Tangshan, Hebei China
Sinopharm Dongfeng General Hospital, Shiyan, Hubei China
Huazhong University of Science and Technology, Wuhan, Hubei 430000 China
Sichuan University, Chengdu, Sichuan China
Eligibility Criteria
Inclusion Criteria: 1. Type 2 diabetes mellitus diagnosed by a physician based on the diagnostic criteria outlined in the Guideline for the Prevention and Treatment of Diabetes Mellitus in China (2024 Edition); 2. Men or women aged 40-79 years; 3. Convenient access to the study centers and permanent residence in the vicinity for the next five years; 4. Voluntary participation and signed written informed consent. Exclusion Criteria: 1. History of clinical cardiovascular disease (including myocardial infarction, treatment or hospitalization for heart failure, stroke, and coronary revascularization) within the past 6 months; 2. History of severe diabetic microvascular complications (diabetic nephropathy with an estimated glomerular filtration rate (eGFR) \< 30 mL/(min·1.73m²), proliferative diabetic retinopathy, confirmed diabetic peripheral neuropathy with abnormal nerve conduction studies or small fiber neuropathy testing); 3. History of cancer, excluding non-melanoma skin cancer or cancers with a favorable prognosis; 4. History of kidney stones, hypercalcemia, or hyperparathyroidism; 5. History of severe liver disease, severe kidney disease, severe gastrointestinal disease, severe infectious diseases, severe sarcoidosis or other granulomatous diseases, severe mental illness, or any other condition considered unsuitable for participation judged by the clinic team; 6. Laboratory evaluation: * Blood calcium levels greater than or equal to the normal range for the clinical site's laboratory; * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels higher than 3 times the normal range for the clinical site's laboratory; * eGFR \< 30 mL/(min·1.73m²); 7. Individuals currently taking vitamin D supplements (\>400 IU/day), calcium supplements (\>600 mg/day), yeast β-glucan supplements (\>250 mg/day), or those with a history of allergy or intolerance to vitamin D or prebiotic products; 8. Participation in other clinical trials within the past 3 months; 9. Planning to become pregnant within the next five years, or currently pregnant or breastfeeding.
Conditions Type 2 Diabetes
Phase NA
Enrollment 540
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal of this study is to examine the efficacy of the video-based Diabetes Self-Management Education and Support (DSMES) (hereafter VIDEO), or the video-based DSMES+community health worker (CHW) intervention (hereafter VIDEO+CHW), compared with a wait-list control group (hereafter CONTROL) to improve glycemic control among Chinese Americans with uncontrolled type 2 diabetes in NYC.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Video-Based Diabetes Self-Management Education and Support (DSMES) — The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.
  • Behavioral: Community Health Worker (CHW) Support — CHWs will assess participants' social determinants of health (SDOH) barriers to Type 2 diabetes care and link them to available resources in the community.

Primary Outcomes

  • Hemoglobin A1c (HbA1c) Levels (Baseline)
  • Hemoglobin A1c (HbA1c) Levels (Month 6)
  • Hemoglobin A1c (HbA1c) Levels (Month 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-29
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Lu Hu, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Lu Hu, PhD
646-501-3438
Lu.hu@nyulangone.org
Interventions
  • Behavioral: Video-Based Diabetes Self-Management Education and Support (DSMES) — The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.
  • Behavioral: Community Health Worker (CHW) Support — CHWs will assess participants' social determinants of health (SDOH) barriers to Type 2 diabetes care and link them to available resources in the community.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10016 United States
Eligibility Criteria
Inclusion Criteria: * self-identify as ethnically Chinese; * be above 18 years old; * have a diagnosis of Type 2 diabetes (T2D) in the medical record; * have an HbA1c≥7% in the past 12 months * be willing to participate in video-based interventions; and * possess a smartphone or, if they do not have one, be willing and able to use a study smartphone. Exclusion Criteria: * unable or unwilling to provide informed consent; * unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment); * unwilling to accept randomization assignment; * is pregnant, plans to become pregnant in the next 6 months, or becomes pregnant during the study; or * is breastfeeding (e.g., they may have potential dietary restrictions).
Conditions Diabetes Mellitus, Diabetes Mellitus, Ty...
Phase NA
Enrollment 432
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The PACT Study is a cluster randomised trial of a health coach-led patient activation program in type 2 diabetes. The goal of this clinical trial is to evaluate the effectiveness of a health coaching intervention (PACT program) led by Care Coaches (trained lay persons), in adult participants with sub-optimally controlled Diabetes Mellitus, as compared to participants undergoing routine care for diabetes (Usual Care). The primary outcome of interest is change in Glycated Haemoglobin (HbA1c) levels over 3 months, 6 months and 12 months. Secondary outcomes include changes in blood pressure, low-density lipoprotein-cholesterol (LDL-C) levels, body mass index (BMI), self-reported diabetes self-care behaviours, self-efficacy, health-related quality of life, and diabetes-related distress, over 3, 6 and 12 months. Participants in the Intervention arm will undergo the PACT Program, which is a 3-month long health coaching program led by a care coach. Participants review their motivators, health parameters, self-care behaviours, and set goals for improving their diabetes using a PACT report. Subsequently, they will receive fortnightly motivational and problem solving support via telephone or WhatsApp messaging over a 3-month duration, and will return to routine care after 3 months. Participants in the Usual Care arm will have routine care of their diabetes treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Patient Activation through Conversations (PACT) Program — Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
  • Behavioral: Usual Care — Routine Chronic Disease care

Primary Outcomes

  • HbA1c (24 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-22
Completion: 2028-04-22
Eligibility
Age: 21 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 432 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Healthcare Group Polyclinics
Collaborators: National Healthcare Group, Singapore
Principal Investigators:
  • Sabrina Kay Wye Wong, MBBS (PRINCIPAL_INVESTIGATOR) - National Healthcare Group Polyclinics
Contact Information
Study Contact:
Jun Hwee Benjamin Lee, MBBS
+6563553000
benjamin_jh_lee@nhgp.com.sg
Sabrina Kay Wye Wong, MBBS
+6563553000
sabrina_kw_wong@nhgp.com.sg
Jun Hwee Benjamin Lee
+6563553000
benjamin_jh_lee@nhgp.com.sg
NHGP Geylang Polyclinic
Interventions
  • Behavioral: Patient Activation through Conversations (PACT) Program — Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
  • Behavioral: Usual Care — Routine Chronic Disease care
Study Locations (3 sites)
NHGP Geylang Polyclinic, Singapore, 389707 Singapore
NHGP Ang Mo Kio Polyclinic, Singapore, 569666 Singapore
NHGP Woodlands Polyclinic, Singapore, 738579 Singapore
Eligibility Criteria
Inclusion Criteria: * Individuals with a diagnosis of Type 2 Diabetes Mellitus who are enrolled in Teamlets in NHGP * Age between 21 to 64 years old * HbA1c level of more than 8% in the last 6 months Exclusion Criteria: * History of acute coronary syndrome in the past 3 months * History of stroke or transient ischaemic attacks in the past 3 months * History of end stage organ failure (liver cirrhosis, cardiac failure, latest eGFR \<30 mL/min/1.73m2 in the last 6 months) * Cancer requiring treatment in the past 5 years. * Active psychiatrist follow up * Social issues that are significant enough for follow-up or referral with a medical social worker within the last 12 months * Women who are pregnant or breastfeeding * Patients who are enrolled in other current diabetes-related interventional studies * Inability to provide written consent for the study protocol and able to commit to the study duration.
Conditions Diabetes Type 2
Phase NA
Enrollment 140
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Dulce Digital Text Messaging Intervention — Text-based education support program: * Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months. * Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading.
  • Other: CGM Device — Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.

Primary Outcomes

  • HbA1c (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-03
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Scripps Whittier Diabetes Institute
Principal Investigators:
  • Athena Philis-Tsimikas, MD (PRINCIPAL_INVESTIGATOR) - Scripps Health
Contact Information
Study Contact:
Kallie Brown, PhD
858-258-3555
brown.kallie@scrippshealth.org
Athena Philis-Tsimikas, MD
877-944-8843
philis-Tsimikas.athena@scrippshealth.org
Athena Philis-Tsimikas, MD
877-944-8843
tsimikas.athena@scrippshealth.org
Scripps Whittier Diabetes Institute
Interventions
  • Other: Dulce Digital Text Messaging Intervention — Text-based education support program: * Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months. * Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading.
  • Other: CGM Device — Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
Study Locations (1 sites)
Scripps Whittier Diabetes Institute, San Diego, California 92037 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes * Are not currently using a CGM * Are not using insulin therapies * Speak English, Spanish or Arabic * Have A1c between 7.5% and 12.0% in last 90 days * Have a cellphone that can receive/send text messages and counts steps Exclusion Criteria: * Are using insulin therapies * Are pregnant * Are currently using a CGM * Are currently participating in another diabetes-related study
Conditions Asthma
Phase NA
Enrollment 216
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide, and ICS therapy is essential for controlling symptoms and preventing severe exacerbations. However, many patients struggle with adherence, especially those with anxiety about ICS side effects. RAMICS is a multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of personalized telephone-based interventions, including medication education, progressive muscle relaxation (PMR), motivational interviewing (MI), and lung rehabilitation guidance. The study will enroll 216 adult asthma patients with poor ICS adherence and clinically significant anxiety. Participants will be randomized into two groups: the intervention group, receiving weekly telephone sessions, and the control group, receiving standard follow-up calls. The study aims to assess improvements in ICS adherence, reductions in anxiety and depression, better asthma symptom control, and enhanced quality of life. Outcomes will be evaluated immediately after the 8-week intervention and during a 3-month follow-up. By addressing both psychological and medication adherence challenges, this research aims to provide practical solutions for improving asthma management.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Personalized Telephone-Based Psychological Support — This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components: 1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects. 2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being. 3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change. 4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels.
  • Behavioral: Standard Care with Weekly Follow-Up Calls — Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.

Primary Outcomes

  • ICS Adherence (Baseline, Week 4 (mid-intervention), Week 8 (end of intervention), and 3-month follow-up.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-13
Completion: 2027-06-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Ningbo University
Contact Information
Study Contact:
Chao Cao
+86-0574-87089878
caocdoctor@163.com
Shiyi He
+86-0574-87089878
shiyihii@163.com
Dongju Su
0451-86605222
hydsdj@126.com
Second Affiliated Hospital of Harbin Medical University
Interventions
  • Behavioral: Personalized Telephone-Based Psychological Support — This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components: 1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects. 2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being. 3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change. 4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels.
  • Behavioral: Standard Care with Weekly Follow-Up Calls — Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.
Study Locations (11 sites)
Second Affiliated Hospital of Harbin Medical University, Harbin, China
Anhui Chest Hospital, Hefei, China
The First Affiliated Hospital of Anhui Medical University, Hefei, China
The Second Affiliated Hospital of Anhui Medical University, Hefei, China
Jingzhou Central Hospital, Jingzhou, China
Haishu District People's Hospital, Ningbo, China
Ningbo Medical Center Lihuili Hospital, Ningbo, China
Qianhu Hospital, Ningbo, China
The First Affiliated Hospital of Ningbo University, Ningbo, China
Ninghai County First Hospital, Ninghai, China
Eligibility Criteria
Inclusion Criteria: 1. Age Requirement: Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions. 2. Diagnosed Asthma: 1. Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months. 2. Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects. 3. ICS Treatment History: 1. Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect evaluation. 2. No major changes to asthma control medication regimen in the past six months, ensuring adherence and intervention outcomes are not confounded by treatment changes. 4. Poor Medication Adherence: Identified using the Medication Adherence Report Scale (MARS-10), with an average score \<4.5, indicating suboptimal adherence. 5. Presence of Anxiety Symptoms: 1. Confirmed through the Hamilton Anxiety Rating Scale (HAMA), with a score ≥14, indicating clinically significant anxiety. 2. Anxiety symptoms must be related to asthma treatment, particularly concerns about ICS side effects or long-term use, ensuring the psychological intervention targets relevant issues. 6. Ability to Communicate by Phone: Participants must have stable access to a phone and be willing to engage in telephone-based psychological interventions. 7. Stable Health Condition: Asthma status must be stable, with no acute exacerbations or significant changes in the past month. Exclusion Criteria: 1. Severe Psychiatric or Cognitive Disorders: 1. Diagnosis of major psychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, or other severe mental illnesses within the past six months, based on DSM-5 criteria. 2. Presence of cognitive impairments or neurological conditions, such as dementia or post-stroke complications, that may affect comprehension or adherence to the intervention. 3. Current psychiatric treatment involving antipsychotics, antidepressants, or sedatives that could interfere with the intervention's outcomes. 2. Substance Abuse or Dependence: History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances. 3. Severe Comorbidities: 1. Uncontrolled respiratory or cardiovascular conditions, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, heart failure, or uncontrolled hypertension, that could significantly impact asthma control and overall health. 2. Chronic diseases requiring long-term systemic corticosteroid therapy, such as rheumatic or autoimmune diseases, that may interfere with ICS treatment and study outcomes. 4. Pregnancy or Lactation: Pregnant or breastfeeding women are excluded due to the unclear risks of ICS treatment and anxiety management interventions in these populations. 5. Allergic Bronchopulmonary Aspergillosis (ABPA) or Related Conditions: Diagnosed ABPA or other respiratory diseases with mechanisms distinct from asthma, which could confound the assessment of ICS treatment effects. 6. Participation in Other Interventional Clinical Trials: Participation in another interventional clinical trial within the past three months, particularly those involving respiratory diseases or medication adherence management, to avoid confounding effects on outcomes. 7. Incompatibility with Telephone-Based Interventions: Inability to reliably receive or engage in telephone-based psychological interventions due to hearing impairments, communication barriers, or other reasons. 8. Adverse Reactions to Psychological Interventions: Documented refusal of or adverse reactions to psychological interventions, such as phone-based relaxation or motivational interviewing, that could affect the feasibility and effectiveness of the study. 9. History of Major Surgery or Hospitalization: History of major surgery or hospitalization (unrelated to asthma) within the past six months that might impact current health status and introduce bias into the study outcomes.
Conditions Respiration Disorders, Respiratory Disea...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this single-centre observational study conducted at the Royal Hospital for Children in Glasgow, Scotland, is to employ a multi-omics approach to investigate the "gut-lung axis" in health and disease. Part A is a cross-sectional study design investigating the postulated bidirectional link between the gut and lung microbiomes in children suffering from respiratory or gastrointestinal conditions. Children with no GI or respiratory issues attending for orthopaedic care will be used as a benchmark for a healthy gut-lung axis. The main questions we aim to answer are: * What does a healthy gut-lung axis look like? * Do children with respiratory issues show an altered gut microbiome? * Do children with GI issues show an altered lung microbiome? Part B is a longitudinal study design, that aims to assess the effects of biologics on the gut-lung axis by comparing the gut and lung microbiomes in children with asthma at two time-points who are indicated to start biologics therapy (Asthma treatment) or will not receive biologics therapy (asthma control). Participants will provide: * airway samples (to investigate the lung microbiome) * blood samples (to assess inflammatory and metabolic factors which may mediate communication between the two sites) whilst under general anaesthetic for a treatment related to their standard of care * stool samples (to assess gut microbiome) * dietary information (food diary and/or food frequency questionnaire) to assess relationships between diet and the gut-lung axis.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Other: observational only - no interventions as part of study — Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.

Primary Outcomes

  • Assess differences in gut and lung microbiota diversity between groups (At admission on a single day)
  • Assess changes in gut and lung microbiota in children with asthma receiving biologics (Measurement 1 at baseline. Measurement 2 anywhere from 8-52 weeks.)
  • Determine mediators of gut-lung axis in health and disease (At admission on a single day. Between Timepoints A (baseline) and B (from 8-52 weeks) in asthma arm.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-04
Completion: 2028-05-01
Eligibility
Age: 0 Years – 16 Years
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NHS Greater Glasgow and Clyde
Collaborators: University of Glasgow
Principal Investigators:
  • Ross J Langley, MRCPCH (PRINCIPAL_INVESTIGATOR) - NHS Greater Glasgow and Clyde Board HQ
Contact Information
Study Contact:
Ross J Langley, MRCPCH
0141 451 6683
ross.langley@ggc.scot.nhs.uk
Ross J Langley, MRCPCH
0141 451 6683
ross.langley@ggc.scot.nhs.uk
NHS Greater Glasgow and Clyde: Royal Hospital for children, Glasgow
Interventions
  • Other: observational only - no interventions as part of study — Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
Study Locations (1 sites)
NHS Greater Glasgow and Clyde: Royal Hospital for children, Glasgow, Glasgow, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Any infant/child/young person admitted to the RHC, Glasgow for an elective bronchoscopy or GI endoscopy. * Any infant/child attending for an emergency/elective orthopaedic operation without active respiratory or gastrointestinal conditions or receiving treatment for either condition. (Age range birth to 16 years for all groups recruited). * Any child attending respiratory department at RHC who can induce sputum and is having a blood sample taken, with latter part of standard of care. * Any infant/child/young person admitted to RHC for a clinical care appointment with Asthma/wheeze before commencement of biologics therapy (treatment group). * Any child admitted to RHC with asthma/wheeze not indicated for biologic therapy (asthma control group). Exclusion Criteria: * Use of antibiotics by the day of admission or have used antibiotics in the previous month (unless prophylactic antibiotics \> 1 month use). * Any person 17 years old and above. * Any child known to be infected with, or at high risk of having had exposure to HIV, hepatitis B or hepatitis C viruses * . Any child and/or parent/guardian who cannot understand the English language where consent would be unethical. * Any child with Asthma currently receiving Biologics therapy (unless recruited via bronchoscopy route).
Conditions Gestational Diabetes Mellitus, Postpartu...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: The gestational diabetes mellitus and perinatal depression are both global public health issues with high prevalence. Non-perinatal diabetes mellitus and depression are confirmed to have reciprocal influence, which is bidirectional relationship. However, there are still no any confirmations of relationship in the perinatal period. The reason could be that these kinds of studies mostly had been done for postpartum depression, they had rarely been discussed with a clearly sequential influence between gestational diabetes mellitus and perinatal depression. Additionally, there have not been so many Asian countries which been done this kind of studies, therefore, this study will focus on the relationship of gestational diabetes mellitus and perinatal depression. Purpose: This study will discuss the bidirectional relationship of gestational diabetes mellitus and perinatal depression. In the other words, the prenatal depression influences on gestational diabetes mellitus, and vice versa. Those changeable factors, such as social support, health behavior, prenatal body index, weight gain during pregnancy, perinatal complications…etc, will be tested for whether they could be regulators or not between the gestational diabetes mellitus and perinatal depression.Afterwards, a part of participants with diagnosis of gestational diabetes mellitus will receive the intervention of health education to influence the health behavior, then depression and other obstetrics and gynecological results will be tested for effects.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Clips Intervention — A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
  • Device: Structured Questionnaire Only — A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.

Primary Outcomes

  • Number and percentage of participants with interventional health education as accessed by the questionnaire of EPDS change from baseline within the period from 22nd week of pregnancy to 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the self-drafted questionnaire of social support change from baseline within the period from 22nd week of pregnancy to 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the questionnaire of PPAQ change from baseline within the period from 22nd week of pregnancy to 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the self-drafted questionnaire of habit of diet change from baseline within the period from 22nd week of pregnancy to 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the medical record of maternal body weight in kilograms change from baseline of pre-pregnancy within the 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the medical record of maternal BMI in kg/m^2 change from baseline of pre-pregnancy within the 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the questionnaire of knowledge and self-management of gestational diabetes mellitus change from baseline from 22nd week of pregnancy to 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
  • Number and percentage of participants with interventional health education as accessed by the self-drafted questionnaire of health belief change from baseline within the period from 22nd week of pregnancy to 6 months after delivery. (From 22nd week of pregnancy to 6 months after delivery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-26
Completion: 2026-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Collaborators: Mackay Memorial Hospital, Taiwan Adventist Hospital, Taipei Veterans General Hospital, Taiwan, Dianthus MFM Clinics
Principal Investigators:
  • HUNG-HUI CHEN (PRINCIPAL_INVESTIGATOR) - National Taiwan University Hostiptal
Contact Information
Study Contact:
HUNG-HUI CHEN
886-2-2394-7109
hunghuichen@ntu.edu.tw
Interventions
  • Behavioral: Clips Intervention — A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
  • Device: Structured Questionnaire Only — A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, 100 Taiwan
Eligibility Criteria
Inclusion Criteria: * 1\. The diagnosis of gestational diabetes mellitus. * 2\. No any history of disease\* before the pregnancy or do have history of disease\* without taking any medicines. (\*disease, eg. hypertension, diabetes mellitus, hyperthyroidism...etc.) * 3\. No recurrent pregnancy loss and stable condition in the first trimester of pregnancy. * 4\. Using smart phone. * 5\. Being willing to participate in this study. Exclusion Criteria: \- 1. No diagnosis of diabetes mellitus before pregnancy.
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 350
Locations 40 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: AXS-05 — Up to 10 weeks in open-label period; Up to 26 weeks in double-blind period
  • Drug: Bupropion — Up to 26 weeks in double-blind period

Primary Outcomes

  • Time from randomization to relapse of depressive symptoms (up to 26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-12-27
Completion: 2026-03
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Axsome Therapeutics, Inc.
Contact Information
Study Contact:
Study Director
+1 (212) 332-5061
axs-05-mdd-401@axsome.com
Interventions
  • Drug: AXS-05 — Up to 10 weeks in open-label period; Up to 26 weeks in double-blind period
  • Drug: Bupropion — Up to 26 weeks in double-blind period
Study Locations (40 sites)
Clinical Research Site, Bellflower, California 90706 United States
Clinical Research Site, Lafayette, California 94549 United States
Clinical Research Site, Oceanside, California 92056 United States
Clinical Research Site, Redlands, California 92374 United States
Clinical Research Site, Riverside, California 92506 United States
Clinical Research Site, San Diego, California 92103 United States
Clinical Research Site, Upland, California 91786 United States
Clinical Research Site, Brandon, Florida 33511 United States
Clinical Research Site, Doral, Florida 33122 United States
Clinical Research Site, Hialeah, Florida 33012 United States
Eligibility Criteria
Inclusion Criteria: * Currently meets DSM-5 criteria for diagnosis of MDD without psychotic features * Current major depressive episode of at least 4 weeks in duration Exclusion Criteria: * Previously participated in another clinical study of AXS-05; received any investigational drug or device treatment within 30 days of (Screening) Visit 1, or has been prescribed Auvelity. * Unable to comply with study procedures * Medically inappropriate for study participation in the opinion of the investigator
Conditions Late Life Depression
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression in the elderly, or "late life depression" (LLD), is often considered to be homogeneous, legitimizing standardized treatment. Yet the literature suggests that there are different forms of LLD, with different pathophysiology, course and treatment. Our experience has led us to identify an "anergic" form, marked by adynamia and anhedonia (anergic depression, AnD). Highly represented among LLDs, it readily resists the usual antidepressants, so that its course is often chronic. Thanks to the "Chronic Anergic Depression Open Trial", the investigators were able to show that AnD responds to dopaminergic (DA) molecules. Therefore the invastigators hypothesized a pathophysiology linked to dysfunction of the mesolimbic DA system. However, not all patients would present the same form: two subgroups could be isolated, each contributing equally. The first corresponds to patients for whom the episode is a recurrence, the so-called "early onset depression" (EOD). The first episode occurs at 34 ±16 years of age and is frequently associated with a personality disorder (73%). The index episode usually lasts 6 ±3 years and is typically associated with anxiety (96%). The second group corresponds to the onset of primary depression after the age of 60, known as "late onset depression" (LOD). The index episode occurs at around 71 ±6 years of age, in people with no premorbid personality disorders. The episode is shorter (3 ±1 years) and anxiety is frequent (75%) but less marked. These patients showed a high propensity for a course compatible with synucleinopathies, but often less rapid than that of the classic forms of these diseases. The investigators hypothesize that within AnD, EOD and LOD present different pathophysiologies, and that this difference is observable on functional magnetic resonance imaging (MRI): LOD patients should present a greater reduction in functional connectivity in the mesolimbic system. The investigators make the subsidiary hypothesis that LODs also show a structural alteration observable with other types of MRI measurements, i.e. multiparametric imaging.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Functional MRI with EEG per MRI — 2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent. Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,

Primary Outcomes

  • VTA - mesolimbic system functional connectivity (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-17
Completion: 2027-03-01
Eligibility
Age: 60 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Strasbourg, France
Principal Investigators:
  • Ludovic DORMEGNY-JEANJEAN Doctor (PRINCIPAL_INVESTIGATOR) - Department of Physiology and Funtional Explorations at Strasbourg University Hospitals
Contact Information
Study Contact:
Ludovic DORMEGNY-JEANJEAN Doctor
+33388116921
l.jeanjean@unistra.fr
Ludovic DORMEGNY-JEANJEAN
0033388116353
l.jeanjean@unistra.fr
Hôpitaux Universitaires de Strasbourg
Interventions
  • Other: Functional MRI with EEG per MRI — 2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent. Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,
Study Locations (1 sites)
Hôpitaux Universitaires de Strasbourg, Strasbourg, Grand Est 67000 France
Eligibility Criteria
Inclusion Criteria: * Patient aged 60 (inclusive) to 90 years (exclusive) * Patient presenting with active or remitted anergic depression according to the operational criteria of the "Chronic Anergic Depression Open Trial" (1) confirmed by two psychiatrists involved in the study: * Early Onset Depression (EOD) group: with at least one history of depression before age 60 * Late Onset Depression (LOD) group: no history of depression before age 60 * Patient able to understand the objectives/risks of the research and give informed consent * Patient affiliated to a health insurance social protection scheme, beneficiary or dependent Exclusion Criteria: * Contraindication to an MRI scan (including claustrophobia)\* * Psychiatric or organic comorbidity that may interfere with the interpretation of results (e.g. neurovascular disease, psychotic disorder, proven neurodegenerative disease) * Concomitant treatment that may interfere with the interpretation of results (e.g. interferons, corticosteroids) * Patient in exclusion period (from a previous or current study) * Current protective measure (curatorship, guardianship) * Patient under legal protection \* presence of non-removable ferromagnetic foreign body, prosthesis, pacemaker, defibrillator, neurostimulation device, medications delivered by an implanted pump, vascular clip or stent, heart valve or ventricular shunt, implanted device incompatible with 3 Tesla MRI exam, claustrophobia, epilepsy